CNS Pharmaceuticals, Inc (NASDAQ:CNSP) CEO John Climaco tells Proactive the Houston, Texas-based pharmaceutical company has received Fast Track Designation for its lead investigational drug, Berubicin, to treat patients with recurrent glioblastoma multiforme (GBM).
Climaco says the designation only brings it closer to 'move the needle towards approval.' Meanwhile, the company has strengthened its balance sheet with $4.7 million from an at the market offering, giving it a cash runway to Q2 of 2022.